ALT
HEALTHCAREAltimmune Inc
$3.26+0.20 (+6.54%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ALT Today?
No stock-specific AI insight has been generated for ALT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.56$7.73
$3.26
Fundamentals
Market Cap$634M
P/E Ratio—
EPS$-1.00
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume4.1M
Avg Volume (10D)—
Shares Outstanding194.4M
ALT News
21 articles- Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026Yahoo Finance·May 6, 2026
- Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of SecuritiesYahoo Finance·Apr 27, 2026
- Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny StockYahoo Finance·Apr 26, 2026
- Altimmune Catalysts: 2026 Data Readouts and Financing RisksYahoo Finance·Apr 23, 2026
- ALT Stock: What Pemvidutide Means for MASH, AUD and ALDYahoo Finance·Apr 23, 2026
- Is Altimmune a Buy Before Phase III MASH Starts in 2026?Yahoo Finance·Apr 23, 2026
- Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewswire Inc.·Apr 23, 2026
- Altimmune Announces Proposed Underwritten Public Offering of SecuritiesYahoo Finance·Apr 22, 2026
- Independent Non-Executive Director of Altitude Group Picks Up 100% More StockYahoo Finance·Apr 19, 2026
- Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400MMarketbeat·Apr 16, 2026
- ALT Stock and the 2026 MASH Race: Dual Agonists vs. New MechanismsYahoo Finance·Mar 26, 2026
- Altimmune Stock: Neutral Outlook With Big 2026 CatalystsYahoo Finance·Mar 26, 2026
- ALT Pemvidutide Explained: What Makes It Different in MASHYahoo Finance·Mar 26, 2026
- H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver DiseasesYahoo Finance·Mar 25, 2026
- Anti-Aging Protein Research Takes a Step Forward with Cell CloningBenzinga·Mar 24, 2026
- Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays ChatMarketbeat·Mar 12, 2026
- Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next UpMarketbeat·Mar 11, 2026
- Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens ConferenceMarketbeat·Mar 10, 2026
- Altimmune, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 6, 2026
- Altimmune Q4 Earnings Call HighlightsMarketbeat·Mar 5, 2026
- Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial FortificationYahoo Finance·Mar 5, 2026
All 21 articles loaded
Price Data
Open$3.06
Previous Close$3.06
Day High$3.26
Day Low$3.04
52 Week High$7.73
52 Week Low$2.56
52-Week Range
$2.56$7.73
$3.26
Fundamentals
Market Cap$634M
P/E Ratio—
EPS$-1.00
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume4.1M
Avg Volume (10D)—
Shares Outstanding194.4M
About Altimmune Inc
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—